Skip to content
Blackberry Empire – Lifestyle
Author:
Pharvaris N.V.
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
June 15, 2026
Pharvaris Announces Annual General Meeting of Shareholders
June 11, 2026
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
May 29, 2026
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 12, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 12, 2026
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 12, 2026
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
May 8, 2026
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
April 20, 2026
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
April 2, 2026
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
March 20, 2026
1
2
Next Page
→